Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.
